EDITORIAL

Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only

A D Struthers

Correspondence to:
Correspondence to:
Professor Allan Struthers, Department of Clinical Pharmacology, Ninewells Hospital & Medical School, Dundee DD1 9SY, UK;
a.d.struthers@dundee.ac.uk

---

Could BNP be a good prescreening test for echocardiography in general rather than a specific test to prescreen for left ventricular systolic dysfunction only?

---

Keywords: B type natriuretic peptide; natriuretic peptides; heart disease; heart failure

Abbreviations: ACE, angiotensin converting enzyme; BNP, B type natriuretic peptide; LV, left ventricular; LVH, left ventricular hypertrophy

In the early 1990s, the idea first arose that plasma concentrations of B type natriuretic peptide (BNP) might help target scarce cardiac investigations towards the most deserving.¹ This mainly referred to the possibility that BNP could detect which patients had heart failure and which did not. This was based on the fact that echocardiography slots were limited, and that heart failure was hard to diagnose accurately on clinical grounds. The need for correct targeting of echocardiography increased when it was fully realised that clinical heart failure was a heterogeneous entity² and that the treatments which produced major benefit (angiotensin converting enzyme (ACE) inhibitors and ß blockers) were only of definite benefit in those with left ventricular (LV) systolic dysfunction.

A huge amount of work then went in to establishing how well BNP identified either heart failure or LV systolic dysfunction.^3,4 The bottom line of this work is that a normal . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

WEB TOP TEN
Heart 2002 87: 345. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Redwine, L. S., Mills, P. J., Hong, S., Rutledge, T., Reis, V., Maisel, A., Irwin, M. R. (2007). Cardiac-related Hospitalization and/or Death Associated With Immune Dysregulation and Symptoms of Depression in Heart Failure Patients. Psychosom. Med. 69: 23-29 [Abstract] [Full Text]  
• Mueller, T., Gegenhuber, A., Dieplinger, B., Poelz, W., Haltmayer, M. (2005). Capability of B-Type Natriuretic Peptide (BNP) and Amino-Terminal proBNP as Indicators of Cardiac Structural Disease in Asymptomatic Patients with Systemic Arterial Hypertension. Clin. Chem. 51: 2245-2251 [Abstract] [Full Text]  
• Galasko, G. I.W., Lahiri, A., Barnes, S. C., Collinson, P., Senior, R. (2005). What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 26: 2269-2276 [Abstract] [Full Text]  
• Rodeheffer, R. J. (2004). Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?. J Am Coll Cardiol 44: 740-749 [Abstract] [Full Text]  
• Panteghini, M. (2004). Role and importance of biochemical markers in clinical cardiology. Eur Heart J 25: 1187-1196 [Abstract] [Full Text]  
• Georges, A., Forestier, F., Valli, N., Plogin, A., Janvier, G., Bordenave, L. (2004). Changes in type B natriuretic peptide (BNP) concentrations during cardiac valve replacement. Eur. J. Cardiothorac. Surg. 25: 941-945 [Abstract] [Full Text]  
• Clerico, A., Emdin, M. (2004). Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review. Clin. Chem. 50: 33-50 [Abstract] [Full Text]  
• Vourvouri, E. C., Schinkel, A. F.L., Roelandt, J. R.T.C., Boomsma, F., Sianos, G., Bountioukos, M., Sozzi, F. B., Rizzello, V., Bax, J. J., Karvounis, H. I., Poldermans, D. (2003). Screening for left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J Heart Fail 5: 767-774 [Abstract] [Full Text]  
• Koch, A, Singer, H (2003). Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 89: 875-878 [Abstract] [Full Text]  
• James, S. K., Lindahl, B., Siegbahn, A., Stridsberg, M., Venge, P., Armstrong, P., Barnathan, E. S., Califf, R., Topol, E. J., Simoons, M. L., Wallentin, L. (2003). N-Terminal Pro-Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV Substudy. Circulation 108: 275-281 [Abstract] [Full Text]  
• Vrtovec, B., Delgado, R., Zewail, A., Thomas, C. D., Richartz, B. M., Radovancevic, B. (2003). Prolonged QTc Interval and High B-Type Natriuretic Peptide Levels Together Predict Mortality in Patients With Advanced Heart Failure. Circulation 107: 1764-1769 [Abstract] [Full Text]